本刊讯(记者陈佳印)类风湿性关节炎是一种免疫性炎症疾病,发病率高,病程长,多发性损害小关节,给患者造成很大痛苦,晚期的关节畸形和功能障碍严重影响患者正常的工作和生活能力。目前临床上可供使用的抗炎药物虽有很多,但均存在着较严重的副作用,由中国医学科学院药物研究所自行研制的,具有自主知识产权的新药——盐酸氯苯哌酮,有望改善这些缺陷,成为用于临床研究的抗类风湿性关节炎新药。根据WHO提供的数据,世界患类风湿性关节炎的病人达 (Reporter Chen Jiayin) Rheumatoid arthritis is an autoimmune inflammatory disease, high incidence, long duration, multiple damage to the facet joint, causing great suffering to patients, advanced joint deformities and dysfunction seriously affect the patient Normal working and living ability. Although there are many anti-inflammatory drugs currently available clinically, there are serious side effects. The new drug with self-owned intellectual property rights, chlordiazepoxide hydrochloride, developed by Institute of Materia Medica, Chinese Academy of Medical Sciences, is expected to improve These deficiencies, as clinical research for anti-rheumatoid arthritis drugs. According to the data provided by WHO, the world suffering from rheumatoid arthritis patients reached